Vaccine Insights
Transmission-blocking vaccines for respiratory viruses: from concept to clinic
By Anika Singanayagam.
Abstract
Mucosal vaccines are widely proposed as a way to block respiratory virus transmission more effectively than systemic vaccines, yet supporting clinical evidence remains scarce. This Commentary outlines the obstacles to demonstrating transmission-blocking efficacy, from the absence of standardized correlates of protection to the limitations of animal and trial models, and considers how controlled human infection models, household studies, and field trials could help generate this evidence to support regulatory engagement and licensure.
Keywords
- Respiratory viral infections research
- Clinical trial
- Respiratory system
- Transmission (telecommunications)
- Block (permutation group theory)
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Virus
- Respiratory tract infections
- Open access
Source
Published in Vaccine Insights. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.